Volume 73, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


Sitamaquine (WR6026) is an 8-aminoquinoline in development for the oral treatment of visceral leishmaniasis (VL). This was an open-label, dose-increasing study to determine the dose-response and safety profile for sitamaquine in Kenyan patients with VL caused by . Patients (mean age 15.9 [range = 5–47] years) received sitamaquine daily for 28 days at one of four doses: 1.75 (n = 12), 2.0 (n = 61), 2.5 (n = 12), or 3.0 (n = 12) mg/kg/day. The primary efficacy outcome was cure (absence of parasites on splenic aspirate) in the intent-to-treat population at day 180. Cure was achieved in 79 (83%) of 95 patients overall, and in 11 (92%) of 12, 49 (80%) of 61, 9 (82%) of 11, and 10 (91%) of 11 patients at sitamaquine doses of 1.75, 2.0, 2.5, or 3.0 mg/kg/day, respectively. The most frequent adverse events during active treatment were abdominal pain (12 [12%] of 97) and headache (11 [11%] of 97), and one patient in each of the 2.5 mg/kg/day and 3.0 mg/kg/day dose groups had a severe renal adverse event. The effects of sitamaquine on the kidney need further investigation. Sitamaquine was efficacious and generally well tolerated in Kenyan patients with VL.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Zijlstra EE, el-Hassan AM, 2001. Leishmaniasis in Sudan. Visceral leishmaniasis. Trans R Soc Trop Med Hyg 95 (Suppl 1): S27–S58. [Google Scholar]
  2. Thakur CP, Sinha GP, Pandey AK, Kumar N, Kumar P, Hasan SM, Narain S, Roy RK, 1998. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? Ann Trop Med Parasitol 92 : 561–569. [Google Scholar]
  3. Seaman J, Boer C, Wilkinson R, de Jong J, de Wilde E, Sondorp E, Davidson R, 1995. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis 21 : 188–193. [Google Scholar]
  4. Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson AD, 1998. Efficacy and safety of liposomal amphotericin B (Am-Bisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 76 : 25–32. [Google Scholar]
  5. Chunge CN, Owate J, Pamba HO, Donno L, 1990. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg 84 : 221–225. [Google Scholar]
  6. World Heath Organization, September 2003. Miltefosine: what next? TDR New. Available from http://www.who.int/tdr/publications/tdrnews/news70/miltefosine.htm.
  7. More B, Bhatt H, Kukreja V, Ainapure S, 2003. Miltefosine: great expectations against visceral leishmaniasis. J Postgrad Med 49 : 101–103. [Google Scholar]
  8. Prasad R, Kumar R, Jaiswal BP, Singh UK, 2004. Miltefosine: an oral drug for visceral leishmaniasis. Indian J Pediatr 71 : 143–144. [Google Scholar]
  9. Dietze R, Carvalho SF, Valli LC, Berman J, Brewer T, Milhous W, Sanchez J, Schuster B, Grogl M, 2001. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 65 : 685–689. [Google Scholar]
  10. Sherwood JA, Gachihi GS, Muigai RK, Skillman DR, Mugo M, Rashid JR, Wasunna KM, Were JB, Kasili SK, Mbugua JM, Kirigi G, Shaefer KU, Oster CN, Fleckenstein LL, Berman JD, Brewer TG, Roberts CR, Johnson AJ, Schuster BG, 1994. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin Infect Dis 19 : 1034–1039. [Google Scholar]
  11. Jha TK, Sundar S, Thakur CP, Felton JM, Sabin AJ, Horton J, 2005. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am J Trop Med Hyg 73 : 871–876. [Google Scholar]
  12. Chulay JD, Bryceson AD, 1983. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 32 : 475–479. [Google Scholar]
  13. National Cancer Institute, 2003. Common Terminology Criteria for Adverse Events version 3.0 (CTCAE). Cancer Therapy Evaluation Program. Available from http://ctep.cancer.gov/reporting/ctc.html.
  14. Yeates C, 2002. Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute). Curr Opin Invest Drugs 3 : 1446–1452. [Google Scholar]
  15. Dutra M, Martinelli R, de Carvalho EM, Rodrigues LE, Brito E, Rocha H, 1985. Renal involvement in visceral leishmaniasis. Am J Kidney Dis 6 : 22–27. [Google Scholar]
  16. Duarte MI, Silva MR, Goto H, Nicodemo E, Amato Neto V, 1983. Interstitial nephritis in human kala-azar. Trans R Soc Trop Med Hyg 77 : 531–537. [Google Scholar]
  17. Salgado Filho N, Ferreira TM, Costa JM, 2003. Involvement of the renal function in patients with visceral leishmaniasis (kala-azar). Rev Soc Bras Med Trop 36 : 217–221. [Google Scholar]
  18. Caravaca F, Munoz A, Pizarro JL, Saez de Santamaria J, Fernandez-Alonso J, 1991. Acute renal failure in visceral leishmaniasis. Am J Nephrol 11 : 350–352. [Google Scholar]
  19. De Brito T, Hoshino-Shimizu S, Neto VA, Duarte IS, Penna DO, 1975. Glomerular involvement in human kala-azar. A light, immunofluorescent, and electron microscopic study based on kidney biopsies. Am J Trop Med Hyg 24 : 9–18. [Google Scholar]
  20. Central Bureau of Statistics Ministry of Planning and National Development, 2003. Kenyan Demographic and Health Survey. Available from http://www.cbs.go.ke/kdhs2003_highlights.html.
  21. Rashid JR, Nyakundi PM, Kirigi G, Kinoti D, Wasunna MK, 2002. Compassionate use of sitamaquine in an HIV-positive patient with visceral leishmaniasis. Trans R Soc Trop Med Hyg 96 : 533–534. [Google Scholar]

Data & Media loading...

Erratum for Figure 1

Erratum for Table 2

Erratum for reference 11

  • Received : 28 Jan 2005
  • Accepted : 19 Jul 2005

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error